Skip to Content
Merck
CN
  • PAK4 suppresses RELB to prevent senescence-like growth arrest in breast cancer.

PAK4 suppresses RELB to prevent senescence-like growth arrest in breast cancer.

Nature communications (2019-08-11)
Tânia D F Costa, Ting Zhuang, Julie Lorent, Emilia Turco, Helene Olofsson, Miriam Masia-Balague, Miao Zhao, Parisa Rabieifar, Neil Robertson, Raoul Kuiper, Jonas Sjölund, Matthias Spiess, Pablo Hernández-Varas, Uta Rabenhorst, Pernilla Roswall, Ran Ma, Xiaowei Gong, Johan Hartman, Kristian Pietras, Peter D Adams, Paola Defilippi, Staffan Strömblad
ABSTRACT

Overcoming cellular growth restriction, including the evasion of cellular senescence, is a hallmark of cancer. We report that PAK4 is overexpressed in all human breast cancer subtypes and associated with poor patient outcome. In mice, MMTV-PAK4 overexpression promotes spontaneous mammary cancer, while PAK4 gene depletion delays MMTV-PyMT driven tumors. Importantly, PAK4 prevents senescence-like growth arrest in breast cancer cells in vitro, in vivo and ex vivo, but is not needed in non-immortalized cells, while PAK4 overexpression in untransformed human mammary epithelial cells abrogates H-RAS-V12-induced senescence. Mechanistically, a PAK4 - RELB - C/EBPβ axis controls the senescence-like growth arrest and a PAK4 phosphorylation residue (RELB-Ser151) is critical for RELB-DNA interaction, transcriptional activity and expression of the senescence regulator C/EBPβ. These findings establish PAK4 as a promoter of breast cancer that can overcome oncogene-induced senescence and reveal a selective vulnerability of cancer to PAK4 inhibition.